Bayer's Kerendia Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults With Type 1 Diabetes and Chronic Kidney Disease
May 22, 2026
May 22, 2026
WHIPPANY, New Jersey, May 22 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on May 21, 2026:
* * *
Bayer's KERENDIA(R) (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
If approved for this investigational new use, KERENDIA(R) (finerenone), a non-steroidal mine . . .
* * *
Bayer's KERENDIA(R) (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
If approved for this investigational new use, KERENDIA(R) (finerenone), a non-steroidal mine . . .